Researchers are still testing and developing drugs and vaccines against COVID-19, a disease caused by the new coronavirus,media reported. Matthew Harper from Stat News provides predictions about when they’re ready. According to some of the key points harper made in his article: First, data from a comprehensive biotechnology innovation organization paper show that there is only a 19.1% chance that treatment for infectious diseases to begin clinical trials will be approved. Moreover, he believes the timetable may change.
The first treatment that Harper discussed is an existing antiviral drug that is already available, but still needs to be tested before it can be approved more widely. Hydroxychloroquine and chloroquine are considered to be one of the methods expected to be used for treatment. Some doctors have also begun to combine hydroxychloroquine with an antibiotic called azithromycin. Unfortunately, the evidence for the efficacy of these therapies is still too limited, and larger clinical trials will take time to complete. Doctors will continue to use these existing drugs to treat sick patients, but it may take a month or more before we know if they are actually working.
Ridsiewe is another existing drug being tested, and its manufacturer, Gilead, is working with a number of researchers and the government on clinical trials. China’s first major study is scheduled to be completed on April 3rd, when some data will be available. Doctors are also trying to use the plasma that cures patients to treat people who are still sick in an attempt to activate their own immune responses. Although this treatment is currently being used, more refined products can take 9 to 18 months to produce.
As for the new treatment, Regeneron Pharmaceuticals has managed to develop artificial antibodies that have proved effective against Ebola, and now hopes to do the same for the new coronavirus. The trial could begin as early as this summer, and for some seriously ill patients, treatment could begin as early as this fall.
Finally, when it comes to vaccines, the best thing real is to be ready by the end of next year. Some research teams are currently working on vaccines, which increases access to available products by the fall of 2021, but, as Rajeev Venkayya of takeda, a Japanese pharmaceutical company, said last week, “just because we started the vaccine program, Doesn’t mean we’re going to get a vaccine at the other end. Moderna hopes to provide vaccines to certain groups, such as health care providers, this fall.